Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing